EGYPTIAN INTERNATIONAL PHARMACEUTICALS (EIPICO)
PHAR

EGX

Current Price
EGP
EGP (%)
Price Upon Recommendation
50.26 EGP
Target Price from Recommendation

52.50 EGP

+4.45%
Holding Period

From 1 to 3 months

Final Recommendation

Buy stock at the current price

Valid Until

May 18, 2025 at 11:59:59 PM

Risk Assessment

Medium

Confidence Score

75.00%

Potential Growth

12.50%

Investment Reason

PHAR demonstrates strong fundamentals in the healthcare sector, a resilient industry amid economic fluctuations. Recent market data shows steady price appreciation with a current price of 50.26 EGP, supported by Egypt's growing demand for healthcare services and favorable government policies.

Overview
Recent Performance

PHAR's price has shown stability, trading between 50.25 (low) and 50.89 (high) in recent sessions, with a previous close at 50.70. The stock aligns with EGX's broader bullish trends in 2024 , .

Economic Factors

Egypt's economic reforms, rising healthcare spending, and EGX's resilience amid regional tensions support PHAR's growth trajectory.

Competitive Positioning

PHAR benefits from Egypt's underpenetrated healthcare market and strategic partnerships, positioning it to capitalize on sectoral growth and infrastructure development.

Analysis Summary

PHAR is poised for short-to-medium-term growth driven by sectoral tailwinds and stable market performance. Risks include regional volatility, but the risk-reward ratio remains favorable.

Key Points
  • Stable price momentum with 50.26 EGP current valuation.
  • 12.5% growth potential driven by healthcare demand.
  • Medium risk with favorable risk-reward ratio.
  • Aligned with EGX's 2024 bullish performance trends.
Recommendations